BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 23606168)

  • 1. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
    Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
    Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of uridine diphosphate glucuronosyl transferase 1A promoter polymorphisms, beta-globin gene haplotype, co-inherited alpha-thalassemia trait and Hb F on steady-state serum bilirubin levels in sickle cell anemia.
    Adekile A; Kutlar F; McKie K; Addington A; Elam D; Holley L; Clair B; Kutlar A
    Eur J Haematol; 2005 Aug; 75(2):150-5. PubMed ID: 16004608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea.
    Bernaudin F; Arnaud C; Kamdem A; Hau I; Lelong F; Epaud R; Pondarré C; Pissard S
    Blood Adv; 2018 Mar; 2(6):626-637. PubMed ID: 29555644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia.
    Heeney MM; Howard TA; Zimmerman SA; Ware RE
    J Lab Clin Med; 2003 Apr; 141(4):279-82. PubMed ID: 12677174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Genetic and Clinical Significance of Fetal Hemoglobin Expression in Sickle Cell Disease.
    Adekile A
    Med Princ Pract; 2021; 30(3):201-211. PubMed ID: 32892201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.
    Green NS; Barral S
    Pediatr Blood Cancer; 2011 Feb; 56(2):177-81. PubMed ID: 20830771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fetal hemoglobin in sickle cell anemia: genetic studies of the Arab-Indian haplotype.
    Ngo D; Bae H; Steinberg MH; Sebastiani P; Solovieff N; Baldwin CT; Melista E; Safaya S; Farrer LA; Al-Suliman AM; Albuali WH; Al Bagshi MH; Naserullah Z; Akinsheye I; Gallagher P; Luo HY; Chui DH; Farrell JJ; Al-Ali AK; Alsultan A
    Blood Cells Mol Dis; 2013 Jun; 51(1):22-6. PubMed ID: 23465615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined and differential effects of alpha-thalassemia and HbF-quantitative trait loci in Senegalese hydroxyurea-free children with sickle cell anemia.
    Gueye Tall F; Martin C; Ndour EHM; Renoux C; Ly ID; Connes P; Gueye PM; Diallo RN; Diagne I; Diop PA; Cissé A; Lopez Sall P; Joly P
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27934. PubMed ID: 31322815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The XmnI (G)gamma polymorphism influences hemoglobin F synthesis contrary to BCL11A and HBS1L-MYB SNPs in a cohort of 57 beta-thalassemia intermedia patients.
    Nguyen TK; Joly P; Bardel C; Moulsma M; Bonello-Palot N; Francina A
    Blood Cells Mol Dis; 2010 Aug; 45(2):124-7. PubMed ID: 20472475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of UGT1A1 promoter polymorphism, α-thalassemia and β
    Batista JVGF; Arcanjo GS; Batista THC; Sobreira MJ; Santana RM; Domingos IF; Hatzlhofer BL; Falcão DA; Pereira-Martins DA; Oliveira JM; Araujo AS; Laranjeira LPM; Medeiros FS; Albuquerque FP; Albuquerque DM; Santos MN; Hazin MF; Dos Anjos AC; Costa FF; Araujo AS; Lucena-Araujo AR; Bezerra MA
    Ann Hematol; 2021 Apr; 100(4):903-911. PubMed ID: 33523291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
    Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do Alpha Thalassemia, Fetal Hemoglobin, and the UGT1A1 Polymorphism have an Influence on Serum Bilirubin Levels and Cholelithiasis in Patients with Sickle Cell Disease?
    de Azevedo LA; Bonazzoni J; Wagner SC; Farias MG; Bittar CM; Daudt L; de Castro SM
    Mol Diagn Ther; 2017 Aug; 21(4):437-442. PubMed ID: 28567595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
    Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
    Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of BCL11A and HMIP-2 polymorphisms on endogenous and hydroxyurea induced levels of fetal hemoglobin in sickle cell anemia patients from southern Brazil.
    Friedrisch JR; Sheehan V; Flanagan JM; Baldan A; Summarell CC; Bittar CM; Friedrisch BK; Wilke II; Ribeiro CB; Daudt LE; da Rocha Silla LM
    Blood Cells Mol Dis; 2016 Nov; 62():32-37. PubMed ID: 27838552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease.
    Lettre G; Sankaran VG; Bezerra MA; Araújo AS; Uda M; Sanna S; Cao A; Schlessinger D; Costa FF; Hirschhorn JN; Orkin SH
    Proc Natl Acad Sci U S A; 2008 Aug; 105(33):11869-74. PubMed ID: 18667698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
    Adekile A; Menzel S; Gupta R; Al-Sharida S; Farag A; Haider M; Akbulut N; Mustafa N; Thein SL
    Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995
    [No Abstract]   [Full Text] [Related]  

  • 17. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.
    Pule GD; Mowla S; Novitzky N; Wiysonge CS; Wonkam A
    Expert Rev Hematol; 2015 Oct; 8(5):669-79. PubMed ID: 26327494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype.
    Bandeira IC; Rocha LB; Barbosa MC; Elias DB; Querioz JA; Freitas MV; Gonçalves RP
    Cytokine; 2014 Feb; 65(2):217-21. PubMed ID: 24290434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HbF-promoting polymorphisms may specifically reduce the residual risk of cerebral vasculopathy in SCA children with alpha-thalassemia.
    Joly P; Bonello-Palot N; Badens C; Pissard S; Chamouine A; Bernaudin F; Bertrand Y; Connes P; Renoux C
    Clin Hemorheol Microcirc; 2021; 77(3):267-272. PubMed ID: 33216016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of fetal hemoglobin response to hydroxyurea.
    Steinberg MH
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.